The motivation is industrial as much as scientific. China’s annual aquaculture yield of fresh sea cucumber exceeds 220,000 tons, generating enormous quantities of protein-rich raw material that conventional processing methods such as drying and rehydration fail to exploit at high value. The researchers, led by Zhongxing Chu of Central South University of Forestry and Technology and colleagues, reasoned that enzymatic hydrolysis could unlock that value in two directions at once: releasing short bioactive peptides with immunomodulatory potential while also reshaping the flavor profile of the resulting ingredient. What has been missing in prior work, they argue, is a systematic account of how protein structure, flavor chemistry, and peptide bioactivity are connected under a defined hydrolysis process.

To make that connection, the team subjected sea cucumber protein with a purity above 90 percent and a collagen content above 82 percent to a sequential three-enzyme digestion using pepsin, trypsin, and enterokinase, each applied at an enzyme-to-substrate ratio of 1 percent for four hours at 37 degrees Celsius. The treatment cleaved roughly 40.72 percent of the available peptide bonds, as measured by the o-phthalaldehyde colorimetric method, producing a hydrolysate dominated by short fragments. A parallel blank control without added enzymes ruled out interference from endogenous proteases in the raw material, ensuring that the observed transformations could be attributed to the deliberate enzymatic process.

The structural consequences of that digestion were documented with an unusually thorough battery of techniques. Scanning electron microscopy revealed that the native protein, an irregular and densely packed sheet-like material with smooth surfaces, was transformed into a porous, sponge-like network riddled with interconnected cavities. Fourier-transform infrared spectroscopy showed a decline in ordered alpha-helical content and a rise in random coil structures, while ultraviolet and fluorescence spectroscopy demonstrated that aromatic amino acids buried in the hydrophobic core had been exposed to the aqueous environment, with the tryptophan emission peak red-shifting from about 330 to 345 nanometers. X-ray diffraction and differential scanning calorimetry completed the picture: the hydrolysate lost the cooperative thermal denaturation behavior characteristic of intact proteins, meaning the small peptides are less prone to coagulation during food processing, a practical advantage for manufacturers.

Flavor, often treated as an afterthought in peptide research, received full analytical attention here. Using headspace solid-phase microextraction coupled with gas chromatography on an Orbitrap mass spectrometer, the team identified 147 significantly differential volatile compounds between the native protein and the hydrolysate, with 74 upregulated after digestion. Aldehydes such as hexanal and (E,E)-2,4-nonadienal, products of unsaturated fatty acid oxidation, drove the green and fatty notes, while heterocyclic compounds including 2-pentylfuran and trimethylpyrazine, likely born of Maillard reactions between newly liberated amino groups and trace reducing sugars, contributed fried and waxy aromas. The multivariate statistical models separating the two sample groups passed rigorous validation with 200 permutation tests, lending confidence to the conclusion that hydrolysis fundamentally remodeled the volatile landscape of the ingredient.

Peptide identification by liquid chromatography tandem mass spectrometry revealed roughly 9.5 amino acids as the average chain length, with most peptides falling between 0.5 and 1.5 kilodaltons, a size range favorable for intestinal absorption. Glycine and glutamine or glutamic acid dominated the amino acid composition, each exceeding 13 percent average abundance, a signature of the (Gly-X-Y) repeating motif of collagen and direct confirmation that the peptides derived from sea cucumber collagen. The peptides were overwhelmingly hydrophilic and weakly acidic, properties that improve dispersibility in aqueous food systems and reduce precipitation, and the high confidence scores of the identifications underscored the reliability of the dataset.

The screening stage is where the study’s integrative design paid off. From the mass spectrometric sequences, the researchers applied a cascade of computational tools: umami and bitterness predictors, the PeptideRanker bioactivity server, a CSM-peptides immunomodulatory model, and safety checks for toxicity, allergenicity, and water solubility. Sixteen high-confidence peptides emerged, and three candidates, FDRGF, CPPGFMG, and FFSLFCLL, cleared the thresholds of umami probability of at least 0.23, bioactivity score of at least 0.97, and non-toxic, non-bitter status. An electronic tongue then arbitrated. FDRGF, a pentapeptide with the sequence phenylalanine-aspartic acid-arginine-glycine-phenylalanine, posted an umami response of 78, second only to monosodium glutamate at 85, with minimal bitterness and astringency. CPPGFMG showed kokumi-like characteristics reminiscent of glutathione, while FFSLFCLL was undermined by noticeable bitterness. FDRGF, with the highest umami probability of 0.557 and an anti-inflammatory score of 0.78, was crowned the dual-function lead candidate.

Computational docking against three key inflammatory targets, tumor necrosis factor, AKT1, and interleukin-1 beta, predicted favorable binding for all three, with the strongest affinity for AKT1 at a binding energy of minus 9.9 kilocalories per mole. One-hundred-nanosecond molecular dynamics simulations in GROMACS confirmed that the complexes remained stable, with root mean square deviation curves converging to the 1 to 3 angstrom range and residues at the binding interface showing reduced flexibility, a sign of specific and durable engagement. These simulations, the authors note, bridge the gap between static docking snapshots and the dynamic behavior of proteins under physiological conditions, providing structural plausibility for the peptide’s presumed mechanism of interfering with inflammatory cascade initiation.

The decisive test came in RAW 264.7 macrophages, a standard mouse immune cell line. At concentrations from 6.25 to 100 micrograms per milliliter, the peptide showed no cytotoxicity, with viability remaining above 95.28 percent. When the cells were challenged with lipopolysaccharide, a bacterial toxin that drives viability down to about 84 percent and triggers classic inflammatory damage, pre-treatment with the peptide restored metabolic activity in a dose-dependent manner, peaking at 50 micrograms per milliliter. Microscopy showed cells recovering their healthy, spread-out macrophage morphology with visible pseudopodia. More tellingly, the peptide dose-dependently reduced intracellular reactive oxygen species, suppressed NF-kappa-B transcriptional activity in a dual-luciferase reporter assay, and downregulated the protein expression of interleukin-1 beta, tumor necrosis factor alpha, interleukin-6, and the inflammatory enzyme COX-2, the molecular machinery of inflammation itself.

The authors are candid about the limits of their evidence. The immunological findings rest entirely on an in vitro macrophage model of lipopolysaccharide-induced injury, which captures anti-inflammatory performance under stress but cannot represent the full sweep of innate and adaptive immune regulation, and the MTS assay measures metabolic activity rather than complete immune function recovery. Quantitative peptide yield and conversion efficiency were also not determined at this stage. Still, the study stands as a template for how modern food science can pursue two goals at once: an ingredient that delights the palate and, at least in cell culture, calms the inflammatory response. Whether the five-letter peptide FDRGF can carry that promise from the petri dish to the dinner plate will depend on animal and human studies, but as a proof of concept for flavor-functional peptides from underexploited marine protein, it is a savory result in every sense.

Subject of Research: Identification of an umami-tasting, anti-inflammatory peptide from enzymatically hydrolyzed sea cucumber protein

Article Title: Screening and identification of a novel umami peptide with in vitro anti-inflammatory potential from sea cucumber protein: Integration of flavoromics, bioinformatic prediction, molecular simulation and experimental validation

Article References: Chu, Z., Long, C., Xu, K., Zhang, X., Qin, D., Hu, Z., Zhou, Y., Luo, F., & Lin, Q. (2026). Screening and identification of a novel umami peptide with in vitro anti-inflammatory potential from sea cucumber protein: Integration of flavoromics, bioinformatic prediction, molecular simulation and experimental validation. Food Chemistry: X, 39, Article 104580. https://doi.org/10.1016/j.fochx.2026.104580

Image Credits: AI Generated

DOI: 10.1016/j.fochx.2026.104580

Keywords: sea cucumber, umami peptide, bioactive peptides, enzymatic hydrolysis, anti-inflammatory, flavoromics, molecular docking, molecular dynamics, RAW 264.7 macrophages, NF-kappa-B, collagen, food chemistry

The research team, led by Bekri Melka Abdo and Sung-Hyen Lee of the Rural Development Administration’s National Institute of Crop and Food Science, set out to test a deceptively simple question: does the liquid used to presoak onion skin matter? Presoaking is usually dismissed as a washing step, a necessary bit of hygiene before the real work of extraction begins. But the authors argue that soaking can hydrate plant tissue, alter cell wall permeability, and change how soluble compounds diffuse out of the matrix. In other words, the soak itself may be a controllable processing variable—one that food manufacturers could tune to steer the chemistry of the final ingredient.

To probe this idea, the team obtained dried inner skins from conventionally grown yellow onions of a single hybrid cultivar lineage, traced through seed import records to a Dutch-bred variety and farmed in the Mungyeong and Yecheon regions of Gyeongsangbuk-do. The skins were soaked at room temperature in one of five solutions: tap water, 5% vinegar, 1% citric acid, a 1:1 mixture of vinegar and citric acid, or 0.3% hydrogen peroxide. Each soak lasted just four, eight, or twelve minutes—a deliberately narrow window chosen to see whether even minimal预处理 could shift the outcome. After rinsing, drying, and grinding, the powders were extracted in two contrasting systems: methanol, a laboratory reference solvent prized for pulling out flavonol aglycones, and hot water at 95°C, a route compatible with food production.

The results, analyzed by two-way ANOVA with Fisher’s least significant difference comparisons, showed a striking pattern: the identity of the soaking solution had a significant main effect on nearly every major parameter, while the duration of soaking—within that tight 4-to-12-minute range—mattered far less. Solution chemistry, not time, was the dominant lever. Citric acid and the vinegar–citric acid mixture produced the highest extraction yields, boosting total solids recovery to roughly 10.5–10.7% in both solvent systems, compared with about 5.8–7% for plain water. But the researchers caution that yield alone is a misleading metric. The acid-soaked samples recovered more non-phenolic material, diluting the phenolic density of the extracts rather than enriching them.

Total phenolic content, measured by the Folin–Ciocalteu assay and expressed as gallic acid equivalents, reached nearly 491 mg/g in water-soaked methanol extracts—the highest of any condition—while dropping to under 400 mg/g in the citric-acid group. The picture flipped, however, when the team turned to hot water. Here, peroxide-soaked skins yielded the strongest total flavonoid content at 918 mg quercetin equivalents per gram, and the highest quercetin glycoside yields in both solvent systems. Targeted UPLC–PDA quantification confirmed that quercetin, the dominant flavonol of onion skin, partitioned overwhelmingly into methanol—accounting for over 61% of the ion signal in the reference extract—while hot-water extracts were richer in protocatechuic acid and other polar constituents. High-resolution UHPLC–Orbitrap mass spectrometry revealed that the two solvents were not simply recovering different amounts of the same chemistry; they were generating compositionally distinct fractions.

Antioxidant performance tracked this compositional divergence. Using the DPPH radical-scavenging assay, the team calculated IC₅₀ values by four-parameter nonlinear regression and found that peroxide-presoaked extracts showed some of the most favorable radical-scavenging potency, alongside vinegar-treated samples. Exploratory contour plots suggested combined process–response patterns linking solution pH, soak duration, and antioxidant strength, though the authors are careful to note that the soaking solutions differed chemically as well as in pH, so the plots describe trends within the tested range rather than a universal pH optimum. The team emphasizes that assays like DPPH and Folin–Ciocalteu measure electron-transfer chemistry in a plate, not physiological efficacy in a body—useful for comparing treatments, but not proof of health benefits.

To add a biological dimension, the researchers screened representative extracts in RAW 264.7 macrophage cells, measuring metabolic activity with an MTS assay and nitric oxide production indirectly through nitrite accumulation via the Griess reaction. The extracts did not markedly reduce metabolic viability at the tested concentrations of 125 to 500 μg/mL, and presoaking-dependent differences in nitrite accumulation were observed within each extract type. Yet the authors are explicit about the limits: the extracts were tested without an inflammatory challenge such as lipopolysaccharide co-treatment, the two extract types were compared at different doses and durations, and nitrite levels cannot be classified as beneficial or harmful without a defined inflammatory model. The macrophage data are presented as hypothesis-generating screening, not evidence of immunological effect.

The practical implications reach into the growing field of food by-product valorization. Onion skin is a concentrated reservoir of quercetin and related flavonoids with well-documented antioxidant relevance, and converting it into a standardized food ingredient aligns with circular-economy and biorefinery principles. This study suggests that process designers should choose soaking solutions according to their target profile: acids to maximize mass yield, neutral water to preserve phenolic density in organic extraction, or carefully controlled mild oxidation to enhance hot-water flavonoid recovery. Because hot water is the route most compatible with industrial food processing, the finding that presoaking can steer hot-water extract composition is particularly relevant to anyone hoping to upcycle onion waste at scale.

The researchers are equally clear about what their work does not establish. The 0.3% hydrogen peroxide condition was an experimental oxidative treatment, not a food-ready process; residual peroxide, oxidation products, removal efficiency, and regulatory compliance would all need validation before any practical use. The study also did not measure structural changes in the skin matrix, so the mechanism behind the peroxide effect—whether enhanced accessibility or chemical transformation—remains unassigned. Translation to industry, the authors write, will require confirmation across harvests and commercial lots, pilot-scale mass and energy balances, stability and sensory testing, food-matrix performance trials, safety assessment, and techno-economic analysis. What the study does deliver is a framework: a demonstration that a step as ordinary as a few minutes of soaking, guided by the right chemistry and matched to the right solvent, can meaningfully reshape the value recovered from one of the world’s most abundant vegetable waste streams.

Subject of Research: How brief presoaking treatments modulate phytochemical recovery, antioxidant capacity, and macrophage responses of onion skin extracts

Article Title: Simple presoaking modulates phytochemical recovery, antioxidant capacity, and macrophage responses of onion skin extracts

Article References: Abdo, B. M., Song, D., Kang, H. J., Im, J. Y., Hwang, I.-G., Choi, A. J., Kwon, S., & Lee, S.-H. (2026). Simple presoaking modulates phytochemical recovery, antioxidant capacity, and macrophage responses of onion skin extracts. Food Chemistry: X, 39, Article 104402. https://doi.org/10.1016/j.fochx.2026.104402

Image Credits: AI Generated

DOI: 10.1016/j.fochx.2026.104402

Keywords: onion skin, phytochemicals, quercetin, antioxidant activity, food waste valorization, presoaking, hot water extraction, flavonoids, RAW 264.7 macrophages, circular economy, Food Chemistry: X, phenolic compounds

A new study published in MicrobiologyOpen reports the isolation and mechanistic validation of Mitsuokella jalaludinii strain PMC73, a gut commensal that its discoverers describe as a

The rationale for looking to the intestine as a therapeutic reservoir in gout rests on a long-recognized but often overlooked facet of urate physiology. While the kidneys excrete the great majority of uric acid each day, roughly one third of renal-independent elimination occurs through the gut, where commensal bacteria capable of degrading urate and its purine precursors participate in what researchers describe as an intestinal uricolytic axis. When this microbial community is intact, urate that is secreted into the intestinal lumen can be metabolized before reabsorption; when dysbiosis depletes these uricolytic populations, more purine substrate recirculates and the systemic urate burden climbs. This ecological perspective reframes hyperuricemia not merely as an enzymatic problem within host cells but as a breakdown in a metabolic partnership between host and microbiome, one that a well-chosen microbial therapeutic could theoretically restore.

The evolutionary context makes this microbial capacity especially interesting to gout researchers. Most mammals possess functional uricase, a hepatic enzyme that converts uric acid into the far more soluble compound allantoin, which is excreted readily in urine. Humans and certain other primates lost uricase activity through a series of mutations during the Miocene epoch, a change frequently attributed to the antioxidant properties of urate or to proposed survival advantages under purine-rich diets. The consequence, however, is that humans depend almost entirely on renal and intestinal excretion to maintain urate homeostasis, and any impairment of either route predisposes to hyperuricemia. Microorganisms retained their uricolytic enzymes, and the urate transporter and uricase machinery of gut bacteria have therefore become attractive targets for understanding how uric acid is naturally degraded outside the liver.

Purine metabolism provides a second, upstream point of microbial intervention. Dietary and endogenous purines are broken down through a cascade in which hypoxanthine is oxidized to xanthine and then to uric acid by xanthine oxidoreductase, the very enzyme targeted by allopurinol and febuxostat. Bacteria in the intestinal lumen can intercept this pathway at multiple levels: some taxa assimilate purine bases directly as nutrients, incorporating them into nucleic acid biosynthesis rather than allowing their conversion to urate; others express enzymes that funnel hypoxanthine and xanthine toward degradation or interconversion routes that bypass uric acid formation. A candidate strain capable of consuming hypoxanthine, as the Mitsuokella isolate was evaluated for, would in principle reduce the substrate available to host xanthine oxidase, offering an indirect complement to xanthine oxidase inhibitor drugs without sharing their hepatic mechanism of action.

The inflammatory arm of gout pathophysiology is equally central to the study’s logic. Monosodium urate crystals do not cause tissue damage simply through mechanical abrasion; they are recognized as danger signals by macrophage pattern recognition receptors, leading to assembly of the NLRP3 inflammasome, a multiprotein complex that activates caspase-1 and enables proteolytic maturation of interleukin-1 beta and interleukin-18. Mature interleukin-1 beta drives the intense neutrophil recruitment, pain, warmth, and swelling characteristic of an acute flare. Because the macrophage sits at the initiating step of this cascade, the RAW 264.7 cell line triggered by synthetic urate crystals provides a reductionist but informative system for asking whether a candidate treatment dampens inflammasome activation, suppresses cytokine release, or limits the oxidative burst that accompanies crystal phagocytosis. Reactive oxygen species generated during this response feed back positively on inflammasome activity, making antioxidant effects and anti-inflammatory effects mechanistically intertwined.

Preclinical models of this kind carry inherent limitations that temper expectations. A murine macrophage line, even one authenticated and mycoplasma-free, cannot reproduce the complexities of human joint biology: the contribution of synovial lining cells, resident mast cells, neutrophil extracellular traps, and the adaptive immune system are all absent. Species differences between murine and human inflammasome regulation are well documented, and doses of crystal or bacterial conditioning media that inhibit cytokine release in vitro may behave differently in vivo, where pharmacokinetics, gut colonization dynamics, and host immune status shape outcomes. For this reason, the macrophage experiments are best understood as mechanistic screening that establishes plausibility and identifies signaling pathways worth interrogating, rather than as proof of clinical efficacy, which will require animal models of hyperuricemia and, ultimately, controlled human studies.

The safety evaluation framework applied to new microbial candidates deserves attention because it differs substantially from conventional drug development. Genomic analysis serves as the first gate: the complete chromosome sequence allows identification of virulence factor genes, toxin-encoding elements, and acquired antibiotic resistance determinants that could compromise clinical use. Average nucleotide identity calculations against reference genomes confirm the taxonomic identity of the strain at species-level resolution, which matters because probiotic safety and function can be strain-specific rather than species-wide. Physical characterization, including assessment of bile tolerance, acid survival, adhesion properties, and hemolytic behavior, then addresses whether the organism can survive gastrointestinal transit and whether it behaves as a commensal rather than an opportunistic pathogen. This layered vetting reflects lessons from rare infections involving lactobacilli and other typically benign bacteria in profoundly immunocompromised patients.

The post-NGP framing articulated by the authors responds to a genuine bottleneck in microbiome therapeutics. Cultivation-independent sequencing surveys over the past fifteen years revealed that a large fraction of gut species had never been cultured in the laboratory, and many of the most immunologically and metabolically active commensals are strict anaerobes that die rapidly on exposure to oxygen. Next-generation probiotics such as Akkermansia muciniphila and Faecalibacterium prausnitzii demonstrated that these organisms can be tamed and formulated, but also highlighted practical obstacles: manufacturing live obligate anaerobes at industrial scale, protecting them through stomach acid and bile, and maintaining viability on the shelf remain unsolved engineering problems for many candidates. Concepts such as pasteurized bacterial preparations and defined bioactive fractions have emerged as workarounds, suggesting that a live organism may not even be necessary if the responsible molecular mediators can be identified.

This is where the boundary between probiotics, postbiotics, and the proposed post-NGP framework becomes conceptually significant. Postbiotics, as defined in a 2021 expert consensus, encompass inanimate microorganisms or their components and metabolites that confer health benefits, effectively decoupling the therapeutic effect from organism viability. The post-NGP idea, as described here, is less a product category than a discovery pipeline: it emphasizes systematic isolation through culturomics, genomic validation, and disease-targeted functional screening before any candidate advances. In gout specifically, such screening can be structured around measurable functional readouts, including the capacity of a strain to consume uric acid or hypoxanthine in defined medium, to modulate inflammasome signaling in immune cells, and to survive physiological stresses encountered during oral administration. This funnel-like design contrasts with older serendipitous approaches in which commercially available strains were repurposed and tested for whatever benefits happened to emerge.

The epidemiological backdrop amplifies the value of any new mechanistic option. Gout burden correlates strongly with metabolic syndrome, nonalcoholic fatty liver disease, and chronic kidney disease, creating a therapeutic dilemma in which patients who most need urate lowering are often those least able to tolerate or benefit from existing drugs, since several require dose adjustment or carry heightened risks in renal impairment. Allopurinol dosing in particular must be reduced in kidney disease, and failure to attain target serum urate levels remains the most common reason for treatment failure in routine practice. Adherence is another persistent obstacle: because urate-lowering therapy is prophylactic rather than symptomatic, and because initiating therapy can transiently provoke flares, many patients discontinue treatment within the first year. An intervention perceived as a natural commensal with a favorable safety profile could, at least hypothetically, improve acceptability, although this presumption awaits evidence from real-world adherence studies.

Regulatory pathways will ultimately shape whether microbiome-derived candidates reach patients. In many jurisdictions, live biotherapeutic products are now treated as a distinct class requiring manufacture under pharmaceutical-grade controls, strain identity confirmation, and demonstration of absence of transferable resistance genes, in addition to conventional efficacy trials. The characterization work reported for PMC73, including complete genome sequencing on a long-read platform, phylogenomic placement among Mitsuokella reference strains, and PCR-based screening for virulence determinants, aligns with the early stages of such a pathway. What remains ahead is the harder translational sequence: demonstration of urate-lowering in animal models of hyperuricemia, evaluation of anti-inflammatory efficacy in crystal-induced arthritis models, pharmacological assessment of colonization and persistence, and finally randomized clinical testing in hyperuricemic and gouty populations. The present study supplies the mechanistic foundation and safety profile that such a program requires, and it illustrates how systematically mining human gut commensals can surface candidates that conventional probiotic development, constrained to a handful of familiar genera, would never have encountered.

Subject of Research: A human gut-derived bacterial strain, Mitsuokella jalaludinii PMC73, evaluated as a next-generation probiotic candidate for lowering uric acid and treating gout.

Article Title: A Post–NGP Mitsuokella jalaludinii as a Therapeutic Candidate for Gout

Article References: Hossain, M. S., Kim, S., Aziz, M. T., Ahmed, I., Shuvo, M. S. H., Yang, H., Jang, Y., Kim, M., Jang, S., Kim, Y., Oh, S., Nam, Y., Seo, H., & Song, H.-Y. (2026). A Post–NGP Mitsuokella jalaludinii as a Therapeutic Candidate for Gout. MicrobiologyOpen, 15(5), Article e70410. https://doi.org/10.1002/mbo3.70410

Image Credits: AI Generated

DOI: 10.1002/mbo3.70410

Keywords: gout, hyperuricemia, Mitsuokella jalaludinii, next-generation probiotics, gut microbiome, uric acid, NLRP3 inflammasome, xanthine oxidase, URAT1, postbiotics, RAW 264.7 macrophages, MicrobiologyOpen